Drägerwerk AG & Co. KGaA

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP

D22938118
SEDOL

5169218
CIK

N/A

draeger.com
LEI: 5493005UFVHY0PPNKD75
FIGI: BBG000BF2304
DRW3

Drägerwerk AG & Co. KGaA
GICS: 35101010 · Sector: Medical equipment · Sub-Sector: -
NAME
Drägerwerk AG & Co. KGaA
ISIN
DE0005550636
TICKER
DRW3
MIC
XETR
REUTERS
DRWG_p.DE
BLOOMBERG
DRW3 GR
EN 728x90
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
In this section you will find transaction histories for short sales.
ai
NALIZER
Short sellers are obliged to report when building up positions from 0.50% and when reducing positions up to 0.50%. If there are open positions >= 0.50% in the reporting registers, these are shown in the following overview.
Two Short sale positions >= 0.50% are currently registered as reportable-relevant
Date Position Holder Position # Action
18.08.2015 JPMorgan Asset Management (UK) Ltd 0,73% 3
07.08.2013 Highbridge Capital Management, LLC 0,50% 1
The overview shows all positions and their last reported status. Please note that when reducing positions, falling below the 0.50% limit means that the mandatory reporting obligations no longer have to be applied. As a rule, it can be assumed that the positions have been completely reduced following a longer period of inactivity. Positions < 0.50% are therefore only of limited significance.
Date Position Holder Position # Action
18.08.2015 JPMorgan Asset Management (UK) Ltd 0,73% 3
16.04.2015 Arrowgrass Capital Partners LLP 0,00% 12
02.12.2014 Pine River Capital Management L.P. 0,00% 13
17.11.2014 Crédit Industriel et Commercial 0,00% 4
07.08.2013 Highbridge Capital Management, LLC 0,50% 1
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements
The information provided in this area is compiled with care and prepared and processed in complex technical process steps. Quality assurance is an integral part of the methods and procedures used. A plausibility check is carried out to the extent that the source data allows. Before further use, especially in the course of any investment decisions, we recommend consulting at least one second independent source for validation.